Entera Bio
Develops oral peptide therapies through its N-Tab delivery platform.
Something off on this page? Send us feedback.
Profile
Develops oral peptide and protein-replacement therapies using N-Tab, with EB613 its most advanced osteoporosis candidate. Its clinical pipeline also includes EB612 for hypoparathyroidism and EB618 for metabolic syndromes, alongside OPKO collaborations on oral peptide programs.
Develops oral peptide and protein-replacement therapies through N-Tab®, a proprietary delivery platform. EB613, its most advanced candidate, is an oral PTH program for osteoporosis; EB612 targets hypoparathyroidism and EB618 targets metabolic syndromes.
In Jerusalem, the clinical-stage business develops its pipeline and pursues selected development and commercial partnerships. OPKO is its documented external-development partner, with collaborations spanning oral OXM and long-acting PTH programs.
Program progress depends on clinical development and regulatory pathways. The long-acting PTH collaboration gives Entera and OPKO shared ownership and development-cost responsibilities, while the oral OXM program has a different ownership and cost-sharing structure.
Company facts
Key statistics
Year to date +71.8% · Average volume (30d) 3.4M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | −$0.08 | −$0.14 | −75.0% | — | $0 | — | +5.92% |
| May 8, 2026Q1 FY26 | −$0.08 | −$0.07 | +12.5% | — | — | — | −10.00% |
| Mar 27, 2026Q4 FY25 | −$0.09 | −$0.07 | +22.2% | — | — | — | −11.50% |
| Nov 14, 2025Q3 FY25 | −$0.09 | −$0.07 | +22.2% | — | — | — | −1.11% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $42.0K | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | −$8.0K | $0 | −$7.0K | $0 | |
| Operating income | −$2.6M | −$2.7M | −$3.3M | −$3.0M | −$3.5M | −$4.6M | |
| Net income | −$2.6M | −$2.7M | −$3.2M | −$3.0M | −$3.5M | −$7.3M | |
| Diluted EPS | −$0.06 | −$0.06 | −$0.07 | −$0.07 | −$0.07 | −$0.14 | |
| Gross margin | 0.0% | — | — | — | — | — | |
| Operating margin | -6,102.4% | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $571.0K · FY22 $134.0K · FY23 $0 · FY24 $181.0K · FY25 $42.0K
Balance sheet, Jun 30, 2026Cash & short-term investments $11.3M · Total debt $425.0K · Total assets $19.5M · Shareholders' equity $7.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 49.29M · Float 40.37M · 81.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| TCG Crossover GP III, LLC | 12.25M | 7.10% | 13G | Aug 4, 2026 |
| Biotechnology Value Fund L P | 9.17M | 5.30% | 13D | Aug 4, 2026 |
| Knoll Capital Management, LLC | 5.88M | 11.93% | 13F | May 15, 2026 |
| Opko Health, Inc. | 3.69M | 8.10% | 13G | Apr 2, 2025 |
| Miranda Jayne Toledano · director, officer: Chief Executive Officer | 774.1K | 1.57% | Form 4 | Jul 16, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 9, 2026 | Geno J. Germano | director | +20,000 | $1.30 |
| Mar 5, 2026 | Sean Ellis | director | +10,000 | $1.23 |
| Feb 9, 2026 | Sean Ellis | director | +18,000 | $1.24 |
| Feb 10, 2026 | Geno J. Germano | director | +20,000 | $1.49 |
| Feb 10, 2026 | Haya Taitel | director | +7,500 | $1.48 |
Peers
- Amgen
Established osteoporosis medicines with bone-building and antiresorptive options
- Ascendis Pharma (ADR)
YORVIPATH PTH replacement for chronic hypoparathyroidism
- AstraZeneca (ADR)
Phase III PTH1R agonist program for chronic hypoparathyroidism
- Septerna
Next-generation oral PTH1R agonists for hypoparathyroidism
- Novo Nordisk (ADR)
Oral GLP-1 obesity medicines and a broad semaglutide franchise
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Entera Bio | $3.03 | −0.33% | $149.3M | — | — | — | — |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Ascendis Pharma (ADR) | $247.91 | 0.00% | $15.40B | 18.7 | 31.9 | 12.6 | +108.2% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Septerna | $38.91 | +0.13% | $1.75B | — | — | 17.7 | +22,375.6% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Median | 21.6 | 18.4 | 6.1 | +9.7% |